MedTrace Logo

Open Label Extension (OLE) of the TDF2 Study, Botswana

NCT04318210 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 229

Last updated 2022-05-13

Study results available
· View outcomes & findings →

Summary

This study is an open label and is an extension to the TDF2 study in which the investigators offered daily oral tenofovir/emtricitabine (TDF/FTC) for a maximum of 12 months to HIV uninfected former participants of the TDF2 study.

Conditions

  • HIV Infections

Interventions

DRUG

Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg

Sponsors & Collaborators

Principal Investigators

  • Allan Taylor, MD, MPH · Centers for Disease Control and Prevention

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-07-31
Completion
2014-07-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04318210 on ClinicalTrials.gov